• PDF: Delivered by email within 12 to 24 hours of placing the order (Mon-Fri)

Triple Analysis: Lung Cancer, Apoptosis and Peptides

  • Publication Date:January 2013
  • Publisher:Bioseeker
  • Product Type: Report
  • Pages:3953

Triple Analysis: Lung Cancer, Apoptosis and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer

The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part II: Apoptosis

The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides

The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Supporting development of integrative molecule, pathway and disease area strategies
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and
return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

  • KEY TOPICS COVERED
  • Part I: Lung Cancer
    • 5.1 The Scope of this Report
    • 6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets)
    • 7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs)
    • 8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies)
    • 9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer)
    • 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies)
    • 11 Disclaimer
    • 12 Drug Index
    • 13 Company Index
  • Figures: Includes 7 Figures
  • Tables: Includes 284 Tables
    • Total Number of Pages:
  • Part II: Apoptosis
    • 5.1 The Scope of this Report
    • 6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets)
    • 7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs)
    • 8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies)
    • 9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications)
    • 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs)
    • Disclaimer
    • 11 Drug Index
    • 12 Company Index
  • Figures: Includes 7 Figures
  • Tables: Includes 315 Tables
  • Part III: Peptides
    • 5.1 The Scope of this Report
    • 6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets)
    • 7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs)
    • 8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs)
    • 9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer
    • 10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications)
    • 11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs)
    • 12 Disclaimer
  • Figures: Includes 5 Figures
  • Tables: Includes 232 Tables
+44 20 8816 8548

Ask a question about Triple Analysis: Lung Cancer, Apoptosis and Peptides

Enter the characters you see in the picture below
Captcha